

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

**雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

### **INSIDE INFORMATION IN RELATION TO POTENTIAL BUSINESS COOPERATION**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, the Laws of Hong Kong).

The board of directors (the “**Board**”) of Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to notify the shareholders (the “**Shareholders**”) and potential investors of the Company that the Company is currently considering the possibility of business cooperation(s) (the “**Potential Business Cooperation**”) with independent third parties.

The Group is reviewing the feasibility, business model and cooperation framework of the Potential Business Cooperation. As at the date of this announcement, discussions are ongoing but no definitive agreement has been agreed with any party. Details in respect of the Potential Business Cooperation, including the business cooperation and framework, have not yet been finalised as at the date of this announcement.

The Potential Business Cooperation, if materialises, will be published by a separate update announcement.

**Shareholders and potential investors of the Company should note that, the Potential Business Cooperation is subject to, among other things, the market conditions and approvals from relevant authorities, the final decision of the Board, and other consideration. Accordingly, shareholders and potential investors of the Company should be aware that, there is no assurance that the Potential Business Cooperation will proceed, or if so, when they may take place. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Jacobson Pharma Corporation Limited**  
**Wu Lai King**  
*Company Secretary*

Hong Kong, 22 November 2017

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Professor Chow Hee Lum, Albert and Mr. Young Chun Man, Kenneth as independent non-executive Directors.*